26 research outputs found
Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?
BACKGROUND: Mefloquine is a clinically important antimalaria drug, which is often not well tolerated. We critically reviewed 516 published case reports of mefloquine adverse effects, to clarify the phenomenology of the harms associated with mefloquine, and to make recommendations for safer prescribing. PRESENTATION: We postulate that many of the adverse effects of mefloquine are a post-hepatic syndrome caused by primary liver damage. In some users we believe that symptomatic thyroid disturbance occurs, either independently or as a secondary consequence of the hepatocellular injury. The mefloquine syndrome presents in a variety of ways including headache, gastrointestinal disturbances, nervousness, fatigue, disorders of sleep, mood, memory and concentration, and occasionally frank psychosis. Previous liver or thyroid disease, and concurrent insults to the liver (such as from alcohol, dehydration, an oral contraceptive pill, recreational drugs, and other liver-damaging drugs) may be related to the development of severe or prolonged adverse reactions to mefloquine. IMPLICATIONS: We believe that people with active liver or thyroid disease should not take mefloquine, whereas those with fully resolved neuropsychiatric illness may do so safely. Mefloquine users should avoid alcohol, recreational drugs, hormonal contraception and co-medications known to cause liver damage or thyroid damage. With these caveats, we believe that mefloquine may be safely prescribed in pregnancy, and also to occupational groups who carry out safety-critical tasks. TESTING: Mefloquine's adverse effects need to be investigated through a multicentre cohort study, with small controlled studies testing specific elements of the hypothesis
Culturing of Human Mesenchymal Stem Cells as Three-dimensional Aggregates Induces Functional Expression of CXCR4 That Regulates Adhesion to Endothelial Cells*S⃞
Culture-expanded human mesenchymal stem cells (hMSCs) are increasingly used
in a variety of preclinical and clinical studies. However, these cells have a
low rate of engraftment to bone marrow or damaged tissues. Several
laboratories have shown that during isolation and subculturing mesenchymal
stem cells quickly lose the expression of CXCR4, the key receptor responsible
for lymphocytes and hematopoietic stem cell homing. Here we show that
culturing of hMSCs as three-dimensional aggregates (hMSC spheroids) restores
CXCR4 functional expression. Expression of CXCR4 inversely correlates with the
secretion of SDF-1 by hMSCs. Cells from hMSC spheroids up-regulate expression
of CD49b, the α2 integrin subunit, and suppress the expression of CD49d,
the α4 integrin subunit. Transfer of cells from the spheroids back to a
monolayer suppresses the expression of CXCR4 and CD49b and restores the
expression of CD49d. Treatment of cells from the spheroids with SDF-1 leads to
CXCR4 internalization and activation of ERK-1,2. Adhesion of hMSCs to human
umbilical vein endothelial cells (HUVECs) was investigated. SDF-1, AMD-3100,
or exposure of HUVECs to hypoxia did not affect adhesion of hMSCs from a
monolayer to HUVECs. Adhesion of cells from hMSC spheroids to HUVECs was
stimulated by SDF-1, AMD-3100, or by exposure of HUVECs to hypoxia.
Stimulatory effects of hypoxia and addition of SDF-1 or AMD-3100 were not
additive. Overall, our data indicate that the expression of CXCR4 by hMSCs
regulates hMSC adhesion to endothelial cells